Entereg Laparoscopic Colon Resection Study
Entereg (Alvimopan) is a peripherally acting mu-opioid receptor antagonist that has been shown to increase postoperative bowel function in patients after open bowel resection surgery. It has been proven safe and effective for short-term in-house treatment. At the present there are several Drug Use Utilization Evaluation studies reporting results involving the use of alvimopan (ENTEREG) in laparoscopic bowel resection patients. However, this study will be the first randomized, prospective, double-blind, placebo-controlled trial looking at this population. We propose that Entereg will decrease the length of stay by one day in the laparoscopic colon resection patient. We wish to perform a voluntary, double-blinded, placebo controlled study. We plan an enrollment population of 250 patients. Twelve milligrams of Entereg will be administered 30 minutes to 5 hours pre-op followed by 12 mg BID, up to 7 days or 15 total doses. The primary endpoint of the study will be length of stay. The time of GI-2 recovery (toleration of solid food and first bowel movement) and time to GI-3 recovery (toleration of solid food, and flatus or bowel movement) will be secondary endpoints.
Estimated Enrollment = 250, Study Start Date: November 2010, Estimated Study Completion Date: May 2012, Estimated Primary Completion Date: Nov 2011.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06102-5037
- Hartford Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
Subject is scheduled to undergo laparoscopic (straight or hand assisted) elective colon resection with primary anastamosis Subject is >18 years of age Subjects can be either male or female Negative pregnancy test (if patient is a premenopausal female) Medically stable as determined by the treating surgeon- i.e., subject has an American Society of Anesthesiologists Physical Status Score of I to III.
Subject understands the study procedures, agrees to participate in the study as per the study protocol, and has voluntarily provided informed consent Patients who will be receiving IV Opioid therapy post surgery for pain management.
Exclusion Criteria:
Subject is pregnant or lactating Subject is currently using opioids or has taken more than 3 doses of opioids (oral or parenteral) in the week prior to surgery.
Subject has complete bowel obstruction Subject is not able to understand the informed consent document or is unable to give informed consent Patients who will receive a thoracic epidural for pain management post surgery. Subject has any medical instability or any condition at screening/enrollment which, in the opinion of the investigator, might confound the results of the study or pose additional risk to the subject during the administration of study procedures.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Placebo komparator: Placebo
|
12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
|
|
Aktiv komparator: Entereg
|
Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
length of stay in days
Tidsramme: 7-10 days s/p discharge
|
7-10 days s/p discharge
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- JOHN002914HE
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Laparoscopic Colonic Resection
-
Seoul National University HospitalRekrutteringLARS - Low Anterior Resection SyndromeKorea, Republikken
-
Ankara UniversityAarhus University Hospital; Dokuz Eylul University; Lokman Hekim ÜniversitesiAfsluttetLARS - Low Anterior Resection Syndrome
-
Zunyi Medical CollegeThe First Affiliated Hospital of Zhengzhou University; Guizhou Provincial... og andre samarbejdspartnereIkke rekrutterer endnuHirschsprung sygdom | Total Colonic Aganglionosis | Duhamel | SoaveKina
-
Sichuan Cancer Hospital and Research InstituteIkke rekrutterer endnuLARS - Low Anterior Resection Syndrome
-
Mariam Hesham Mahmoud Abdelfattah EissaIkke rekrutterer endnuPeriapikal læsion | Root End Resection | Enkelt rodfæstede tænder
-
HEM Pharma Inc.Premier Research Group plcIkke rekrutterer endnuLARS - Low Anterior Resection Syndrome
-
Northern Jiangsu People's HospitalChina-Japan Union Hospital, Jilin UniversityAfsluttet
-
Northern Jiangsu People's HospitalRekrutteringKolorektal cancer | Postoperativ Ileus | LARS - Low Anterior Resection SyndromeKina
-
National Taiwan University HospitalTilmelding efter invitationLavt anterior resektionssyndrom | Endetarmskræft | LARS - Low Anterior Resection SyndromeTaiwan
-
Qufora A/SEVAMEDRekrutteringEndetarmskræft | Gastroenterologi | LARS - Low Anterior Resection SyndromeFrankrig
Kliniske forsøg med Entereg
-
Jamie N. Bakkum-GamezCubist Pharmaceuticals LLCAfsluttetLivmoderhalskræft | Æggelederkræft | Peritoneal kræftForenede Stater
-
Cubist Pharmaceuticals LLCGlaxoSmithKlineAfsluttet
-
Brigham and Women's HospitalMerck Sharp & Dohme LLCRekruttering
-
University of VirginiaMerck Sharp & Dohme LLCAfsluttet
-
University of California, San DiegoAfsluttet
-
Sharon SteinMerck Sharp & Dohme LLCAfsluttet
-
University of Puerto RicoMerck Sharp & Dohme LLCAfsluttet
-
Washington University School of MedicineBarnes-Jewish Hospital; Orthopedic Research and Education FoundationAfsluttet
-
Cubist Pharmaceuticals LLCAfsluttetPostoperativ IleusForenede Stater
-
Cubist Pharmaceuticals LLCGlaxoSmithKlineAfsluttetForstoppelse | TarmdysfunktionForenede Stater, Australien, Canada, Ungarn, Holland, Spanien, Sverige, Frankrig, New Zealand, Norge, Sydafrika, Schweiz